	US 11,873,346 B2
	VISTA antigen-binding molecules
Jerome Douglas Boyd-Kirkup, Singapore (SG); Piers Ingram, Singapore (SG); Dipti Thakkar, Singapore (SG); Zhihao Wu, Singapore (SG); Konrad Paszkiewicz, Singapore (SG); Vicente Sancenon, Singapore (SG); and Siyu Guan, Singapore (SG)
Assigned to Hummingbird Bioscience Pte. Ltd., Singapore (SG)
Filed by Hummingbird Bioscience Pte. Ltd., Singapore (SG)
Filed on Mar. 18, 2020, as Appl. No. 16/823,280.
Application 16/823,280 is a continuation of application No. 16/596,739, filed on Oct. 8, 2019, granted, now 10,633,456.
Application 16/596,739 is a continuation of application No. PCT/EP2019/058036, filed on Mar. 29, 2019.
Prior Publication US 2020/0308308 A1, Oct. 1, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 16/46 (2006.01)

CPC C07K 16/464 (2013.01) [C07K 16/468 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/72 (2013.01)]

13 Claims

1. An antigen-binding molecule comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the antigen-binding molecule binds specifically to and displays cross-reactivity with both to human VISTA and mouse VISTA, wherein the antigen-binding molecule inhibits VISTA-mediated signalling independently of Fc-mediated function, and wherein the antigen-binding molecule comprises:

a VH region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:305

HC-CDR2 having the amino acid sequence of SEQ ID NO:306

HC-CDR3 having the amino acid sequence of SEQ ID NO:307; and

a VL region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:308

LC-CDR3 having the amino acid sequence of SEQ ID NO:43.